NEWS
Cluster's life
23 / 05 / 2013
Mérieux Développement Private Equity Joins Lavorel Medicare as Reference Shareholder
Lavorel Medicare announced today that Mérieux Développement has become a reference shareholder as part of a growth capital financing round, a new ...
17 / 05 / 2013
First round of financing for ElsaLys Biotech
ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M¤ from the ...
16 / 05 / 2013
genOway sign a new partnership in the field of therapeutic proteins
genOway’s technological platform has become an essential source of innovative animal models for biotech development, efficiency and safety ...
30 / 04 / 2013
BIO Chicago 2013: Very successful event for Lyonbiopole and its 19 member companies
Lyonbiopole, world-class competitiveness cluster focused on the fight against infectious diseases and cancers, has participated in “BIO ...
30 / 04 / 2013
ERYTECH’s IPO a remarkable success, raising ¤17.7 million
22 / 04 / 2013
Bio-Modeling Systems and Persistent Systems launch joint strategic Systems Biology initiative
18 / 04 / 2013
ERYTECH announces its IPO on NYSE Euronext Paris regulated market
16 / 04 / 2013
Lyonbiopole will be present with 19 companies from Rhone-Alpes region at BIO
This international exhibition Biotechnology International Convention will take place at Chicago April from 22nd to 25th, 2013
16 / 04 / 2013
EVEON announces the signing of a major industrial partnership with pharma company Alaxia
Eveon and Alaxia are Lyonbiopole's members
15 / 04 / 2013
Appointment of Eric Rougemond at the Presidency of Aguettant
03 / 04 / 2013
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in the U.S
This clinical study will be on Acute Lymphoblastic Leukemia
28 / 03 / 2013
Awards "Next Gem Award" and "Catalyzer Awards" in closing BIOVISION
The eight edition of BIOVISION, the World Life Sciences Forum, closed on March 26th with the « BIOVISION Next Gem Award » and the « BIOVISION ...
28 / 03 / 2013
Forth projects, accredited by Lyonbiopole, obtain public funding from the 15th Call for Projects of
Those forth R&D projects, accredited by Lyonbiopole and submitted to the 15th FUI call for projects, benefit from public funding from the French ...
26 / 03 / 2013
BioXclusters signs a Memorandum of Understanding
with FIPASE
On the occasion of BIOVISION, the World Life Sciences Forum held in Lyon from March 24th to 26th, the 4 European healthcare clusters, partners of the ...
25 / 03 / 2013
"GERLAND: the meeting point of biotechnological innovation"
All major public and private actors invest in Lyon Gerland in future projects that strengthen the dynamics of innovation in the areas of life ...
25 / 03 / 2013
Sanofi and Transgene: Innovative Collaboration for the Production of Immunotherapy Treatment
19 / 03 / 2013
ETHERA realizes a 2nd fundraising for ¤ 3M
12 / 03 / 2013
EyeTechCare raises ¤ 10 million in the fight against glaucoma
Use ultrasound to fight against Glaucoma? This is what offers to make EyeTechCare with this fundraiser will ensure the development of this innovation ...
11 / 03 / 2013
The project IMODI certified by Lyonbiopole will receive ¤ 13.4 M
Oncodesign, a CRO specializing in oncology and OSEO, the arm of the French Public Investm ent Bank which deals with funding for the future,announced ...
07 / 03 / 2013
First Patient In for Poxel's Imeglimin Phase IIb Monotherapy Trial to Treat Type 2 Diabetes
Poxel SA, has announced 7th March, the initiation of a phase IIb clinical trial of Imeglimin, a novel compound in development for Type 2 diabetes
05 / 03 / 2013
BIOVISION Investor Conference 2013
¤ 330M cumulative fund raising by the 35 selected companies
The BIOVISION INVESTOR CONFERENCE Selection Committee, held on March 1st, selected 35 companies to showcase during the BIOVISION Investor Conference ...
26 / 02 / 2013
EDELRIS selected as partner for the European Lead Factory (IMI)
26 / 02 / 2013
The European Commission launches a call for expert for its H2020 programme
26 / 02 / 2013
Mission in China 2013 organised by Lyonbiopole and I-Care from May 26 to 31, 2013
26 / 02 / 2013
Calixar and Synthelis team up to provide unique membrane protein services.
26 / 02 / 2013
CEBR becomes a independent association
19 / 02 / 2013
BIOVISION and Lyonbiopole reveal the selection of innovative projects
The 8th edition of BIOVISION, the World Forum of Life Sciences, held in Lyon from 24 to 26 March 2013, marked a turning point in its history by ...
13 / 02 / 2013
Immune Diversity & Sepsis : a new study by the Hospices Civils of Lyon and ImmunID
08 / 02 / 2013
Listing of Spineway on NYSE Alternext Paris
28 / 01 / 2013
TRUMPF and EndoControl expand their VICKY distribution partnership
23 / 01 / 2013
Imaxio acquires Trolovol® (D-penicillamine)
This acquisition strengthens Imaxio’s pharmaceutical range, which now includes two products sold in France, and will finance the ...
22 / 01 / 2013
Launch of International Centre for Research in Infectious Diseases CIRI
The CIRI promotes an integrated approach for the study of the interactions between host (s) and pathogen(s). It aims not only to be recognized ...
22 / 01 / 2013
An essential act to improve the efficiency of regional ecosystem for innovation
Clara and Lyonbiopole agree to combine their respective strengths to enhance development and transfer of knowledge from research to clinical ...
03 / 01 / 2013
Alizé Pharma announces the launch of the research program PREMAG
This collaborative project of nearly 4 million is to expand the therapeutic potential of AZP-531, analogous to UAG Alizé Pharma, with indications of ...
18 / 12 / 2012
ZOOM on POXEL
Poxel, founded in 2009, is a biopharmaceutical company developing innovative first-in-class drugs, with a primary focus on Type 2 diabetes.
17 / 12 / 2012
Imaxio sign an option agreement license with Merial for developing a vaccine in animal health
This agreement confirms the potential of the technology reengineering antigens Imaxio for improved vaccines and animal health.
17 / 12 / 2012
Development of first-in-class drugs for cancer and inflammatory diseases
EffiKIR is a double-blind placebo-controlled randomized Phase II trial of IPH2102/BMS-986015 as maintenance treatment in elderly patients with Acute ...
16 / 12 / 2012
Creation of Valvena by Vivalis and Intercell
The Management Boards of Vivalis and Intercell announce that they have agreed the terms of a merger to create the newly-named Valneva, a leading ...
10 / 12 / 2012
ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe
Lyon (France) - November 22, 2012 - ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announced ...
04 / 12 / 2012
Operational implementation and launch of the first R & D programs
Dedicated to infectious diseases and mircobiologie Technological Research Institute BIOASTER ensure optimal chain research and innovation through R & ...
27 / 11 / 2012
Lyonbiopole involved in the development of the European roadmap for systems medicine implementation
22 partners are joining forces through the Coordination Action Systems Medicine – CASyM supported by the FP7-Health Directorate of the European ...
Events
28 / 02 / 2013
Great success of the 1st CASyM stakeholder conference on BIOVISION
12 / 10 / 2012
Lyonbiopole Partnering Days, on friday October 12th, 2012 in Grenoble
Focus on
24 / 04 / 2013
FOCUS ON AXO SCIENCE
AXO Science is specialized in the development of high-throughput and multiplexed microarray diagnostic solutions dedicated to the characterization of ...
28 / 03 / 2013
FOCUS ON INDICIA
Indicia Production announces the acquisition of Biotechnologie Appliquée
